Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li>The <keyword id="6373926" type="General" weightage="80" keywordseo="horlicks" source="Orion">Horlicks</keyword> Plus range, a set of specialized brands formulated to solve nutritional deficiencies, has forayed into the segment of Diabetes.</li><li>Diabetes Plus, introduced by Horlicks, is a nutritional beverage that has been designed for Indian adults.</li></ul>India has always been prone to the various risks associated with Diabetes. The country ranks #2 after China, with the prevalence rate of the disease set to double in the next 25 years. While diabetes continues to be an emerging threat with 7.3% of India’s population being diabetic and a further 10.3% being prediabetic, there are almost 1 in 2 diabetics that go undiagnosed*. The major life changes that come with diabetes have also led to dissonance with consumers constantly looking for solutions to help manage diabetes better. Keeping these alarming figures and consumer needs in mind, the Horlicks Plus range, a set of specialized brands formulated to solve nutritional deficiencies, has forayed into the segment of Diabetes. Diabetes Plus, introduced by Horlicks, is a nutritional beverage which has been designed for Indian adults. It contains high fibre (22% of dual blend fibre). Research has shown that a diet rich in fibre helps reduce glucose and lipids in the blood#. <keyword id="12543075" type="General" weightage="20" keywordseo="horlicks-Diabetes-Plus" source="Orion">Horlicks Diabetes Plus</keyword> is high in protein and contains 16 vital nutrients. It contains Fibersol-2 and NUTRIOSE®. These fibres are known to promote satiety and reduce calorie intake. Commenting on importance of diet &amp; lifestyle for diabetes management, Dr Banshi Saboo, President, RSSDI said, “An unhealthy modern diet and low activity patterns are regarded as major drivers of diabetes increase in India and this needs to change. Studies have shown that fiber rich diabetes nutrition (FDN) has multiple benefits, including, improvement in glycemic control, reduction in glucose spikes, lowering of plasma lipid concentrations and weight management in T2DM patients.” Horlicks Diabetes Plus recently introduced its first TVC to highlight the importance of fibre for diabetic patients. Commenting on the TVC, Krishnan Sundaram, Vice President, Nutrition, HUL said “Diabetes is equivalent of a pandemic and India is facing an increasing burden of it with 24 Cr diabetics and prediabetics. We know that, nutrition and lifestyle can play a key role in its management. We are launching Horlicks Diabetes Plus, a supplement specifically formulated for at risk and diabetic individuals. With our communication, we want to educate consumers about the importance of high fibre for diabetics, and how Diabetes Plus which has dual blend high fibre fulfills 26% of your daily fibre requirements." <div type="Youtube" id="Pd3LvWcNpEg" title="Horlicks Diabetes Plus: Dual Blend High Fibre | Helps manage diabetes" thumbUrl="https://i.ytimg.com/vi/Pd3LvWcNpEg/mqdefault.jpg"></div> The copy showcases a concerned diabetic patient looking at reducing his sugar intake but is offered food items that seem to contain a high amount of sugar. While the patient is questioning the prevalence of sugar in various food items, the copy also highlights the importance of adding fiber to one’s diet in addition to reducing sugar in one’s diet. Commenting on the creative insights that went into the making of the film, Sumitra Sengupta, Executive Creative Director, FCB India said “When any one is pre-diabetic or a newly diagnosed diabetic, the immediate reaction is to cut down sugar. Our film opens with a middle-aged man worriedly asking about the sugar content of every food placed before him. But what starts out as being the correct thing to do, suddenly appears inadequate in the light of the Doctor’s announcement that high fiber helps manage Diabetes. This creates a perfect opportunity to introduce Horlicks Diabetes Plus which fulfills 26% of daily fibre needs. We hope it results in change in nutritional behaviour too - of not just reducing sugar, but adding fibre too.” Credits Agency: FCB India Production House: Milestone Films Producer: Ajay Vasu Director: Sandeep Yadav Creative: Swati Bhattacharya, Sumitra Sengupta, Kshitij Chandel Account Mgmnt: Debarpita Banerjee, Siddharth Kapoor, Priyanka Balasubramanian, Vedika Jain Planning &amp; Strategy: Kizie Basu, Aniruddh Subramanian Films Team: Ashish Barot

Horlicks taps into the segment of diabetes; launches a new campaign to highlight the importance of fibre consumption for diabetic patients

<ul class="summary-list"><li>Hospitals in <keyword id="3658" type="COUNTRY" weightage="60" keywordseo="India">India</keyword> have seen a rise in cases of mucormycosis, or "black <keyword id="121368" type="PERSON" weightage="60" keywordseo="fungus">fungus</keyword>," a life-threatening <keyword id="6393040" type="UNKNOWN" weightage="60" keywordseo="infection">infection</keyword>.</li><li>Most of the patients affected are people with <keyword id="6359018" type="UNKNOWN" weightage="60" keywordseo="diabetes">diabetes</keyword> who previously had COVID-19. </li><li>Diabetes, COVID-19, and steroids, which are sometimes used to treat COVID-19, all dampen the immune system, elevating a person's risk of "black fungus."</li></ul>As India grapples with <a href="https://www.businessinsider.com/india-first-country-to-record-400000-single-day-coronavirus-cases-2021-5">record-setting rates of</a> COVID-19 cases, doctors are now facing an uptick in cases of another deadly infection, known as "black fungus."The infection, technically called mucormycosis, appears to be mostly affecting diabetics who have recovered from COVID-19. Mucormycosis is a rare but serious fungal infection in the sinuses and lungs. It can lead to black patches on the nose, blurred or double vision, and one-sided facial swelling, according to the <a href="https://www.cdc.gov/fungal/diseases/mucormycosis/symptoms.html">Centers for Disease Control and Prevention</a>. It's acquired through contact with fungal spores found in soil, plants, and manure.Endocrinologists told Insider that, while black fungus is not new, the pandemic appears to have created the perfect storm.People with diabetes have slightly dampened immune systems, meaning they already have an elevated risk of contracting black fungus. COVID-19, which worse-affects people with diabetes, increases that risk even more. And then there are steroids, a medicine <a href="https://www.businessinsider.com/dexamethasone-steroid-touted-as-coronavirus-breakthrough-drug-risky-mild-cases-2020-6">sometimes used to treat critically ill COVID-19 patients</a>, that can dampen the immune system.While there have not been as many cases reported in other countries, Dr. Deena Adimoolam, a specialist in endocrinology and disease prevention, said all people with diabetes should be taking precautions to protect themselves from infections right now.<h2>Black fungus rates around the world</h2>Black fungus has historically been extremely rare, affecting 900,000 people per year, which is less than 1% of the population, in India a year, according to a <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753159/">study</a> published in 2017. The same study found that only 10,000 people outside of India are affected each year. The US does not have any national surveillance system in place for black fungus: the CDC's rates are based on a study in <a href="https://pubmed.ncbi.nlm.nih.gov/9827260/">1998,</a> finding that there are 1.7 cases per one million people.<h2>Why steroids and COVID-19 increase the risk of black fungus for people with diabetes</h2>People with diabetes, in general, are slightly immunocompromised, because elevated blood sugar impairs the immune system. If diabetics "get an infection, then these patients are more likely to have trouble to fight off the infection," Dr. Rasa Kazlauskaite, an endocrinologist at Rush University Medical Center.Diabetics have high blood sugar levels, too, which is an environment fungus thrives on. "Sugar feeds the fungus and then the fungus is stronger than immune system that is trying to fight it off," Kazlauskaite said. What's more, steroids, which some <a href="https://www.businessinsider.com/dexamethasone-steroid-touted-as-coronavirus-breakthrough-drug-risky-mild-cases-2020-6">evidence</a> has shown has been found to help critically ill COVID-19 patients, may also reduce the immune system's ability to fight off infections because it suppresses the body's immune system. <h2>The risk is particularly high in India</h2>India has the second-highest diabetic population in the world, according to the <a href="https://idf.org/">International Diabetes Foundation's</a> atlas, which amounts to 70.2 million people. Adimoolam said people with diabetes in India are more vulnerable to infection because there may be a genetic risk in this population. "Those in India who have diabetes tend to have a higher risk for developing complications of diabetes like kidney disease or wound infections," Adimoolam said. Adimoolam also said mucor, the fungus linked to mucormycosis, can live on contaminated medical supplies, and that may be driving higher case counts in India. <h2>Don't forgo steroid treatment if you're critically ill with COVID-19</h2>Dr. Yogish Kudva, an endocrinologist at the Mayo Clinic, said if you have diabetes, try to prevent getting COVID-19."The key issue here is to be concerned about covid," Kudva said. He suggests following COVID-19 rules, like <a href="https://www.businessinsider.com/chart-cdc-new-mask-guidance-for-fully-vaccinated-explained-2021-4">wearing a mask in a crowded area</a>, and getting vaccinated. For people with diabetes that have COVID-19 outside of India, Adimoolam said to make sure your blood sugar levels are within a normal range and continue to take prescribed medications. But if you're blood sugar levels high, contact your doctor. If you're a diabetic hospitalized with COVID-19, Adimoolam said let your medical team know that you're diabetic, and "make sure you or your loved ones is advocated for good blood sugar control." Above all else, Adimoolam said don't deny steroids if they're a lifesaving treatment. "Even with high doses of steroids, high blood sugars can be controlled with certain medications."Kazlauskaite also said diabetics hospitalized with COVID-19 should not refuse steroids.

What diabetics should know about the deadly 'black fungus' infections affecting India's COVID-19 patients

New Delhi, Feb 3 () Drug firm Zydus Cadila on Monday said that it has received approval from Drug Controller General of India (DGCI) for Saroglitazar Magnesium used in treatment of diabetes.
 "Zydus Cadila has received the approval from the Drug Controller General of India for use of Saroglitazar Mg in the treatment of type II diabetes mellitus as an add-on therapy with Metformin," the drug firm said in a filing to BSE.
 Type II diabetes is a condition in which cells cannot use blood sugar (glucose) efficiently for energy.
 In India, the drug was previously approved in 2013 for the treatment of hypertriglyceridemia and diabetic dyslipidemia .
 More than one million patients are being treated with Saroglitazar (Lipaglyn).
 "Insulin resistance is one of the primary causes of diabetes and there is a huge unmet medical need for a safe and effective insulin sensitizer. Saroglitazar is an important scientific and medical breakthrough in our effort to develop medicines for patients suffering from type 2 diabetes mellitus," Zydus Group Chairman Pankaj Patel said.
 With increasing cases of diabetes in India, the need to strengthen diabetes management and help patients control their blood sugar levels is of critical importance, he said. SID ANS
ANS

Zydus Cadila gets DGCI nod for diabetes treatment drug

New Delhi, Dec 11 () Drug firm Zydus Cadila on Wednesday said it has launched its affordable oral anti-diabetic Vinglyn brand tablets available in two formulations in India.
 As the product patent on popular diabetes drug Vildagliptin has expired in India on December 9, some domestic drug firms have launched the generic versions of the drug in the country that are much cheaper than the patented medicine.
 "Priced at just Rs 4.95 per tablet, which is almost 1/6th the price at which the patented Vildagliptin was initially launched in India, Vinglyn is now one of the most affordable brands of Vildagliptin for diabetic patients in India," Zydus Cadila said in a statement.
 Vinglyn and Vinglyn M will be marketed by Zydus Healthcare Ltd, it added.
 Zydus Cadila Managing Director Sharvil Patel said, "Fortifying our fight against diabetes, our aim is to make therapies affordable and accessible to patients from across sections of society."
 With Vinglyn, Zydus Cadila believes that it has once again been able to offer this. The access to one of the most affordable gliptin therapies will help a large number of patients suffering from type-2 diabetes, in India, he added.
 With a patient population of almost 77 million diabetics in India, access to affordable therapy is vital for the effective management of the disease, the statement said.
 The drug belongs to the class of oral anti-diabetic agents, known as DPP4 inhibitors, which have shown promise in achieving glycaemic control without deterioration in beta cell function and are one of the recent advancements in diabetes care and management, the statement said.
 Another drug firm Panacea Biotec on Tuesday had said it had launched its VilACT brand tablets available in four formulations, for treatment of type-2 diabetes in India.
 The company had also said its brand will be an affordable and high-quality medicine.
 According to the AIOCD MAT October 2019 data, the total market size of this molecule and its combination is Rs 969 crore and is growing at the rate of 4 per cent, Panacea Biotec had said.
 Shares of Cadila Healthcare, the listed entity of the Zydus group closed at Rs 262.25 per scrip on the BSE, up 0.50 per cent from its previous close. AKT HRS

Zydus Cadila launches affordable oral anti-diabetic tablets in India as drug goes off patent

These are the top-selling anti-diabetes drugs in India

A new study by <keyword id="5069783" type="General" weightage="20" keywordseo="Centre-for-Chronic-Disease-Control" source="Orion">Centre for Chronic Disease Control</keyword>, India (CCDC) on cardiovascular risk reduction in South Asia has demonstrated significant long-term benefits of a multi-faceted quality improvement (QI) strategy, comprising of task sharing, and clinical decision support software (CDSS) with electronic health records, in managing type-2 diabetes in India and Pakistan. The study, published in the prestigious journal PLOS Medicine, highlights the sustained impact of QI interventions on <keyword id="21411276" type="General" weightage="100" keywordseo="diabetes-care" source="keywords">diabetes care</keyword> and associated complications over a median follow-up period of 6.5 years. The burden of diabetes Diabetes control remains a global challenge, leading to severe complications such as <keyword id="22908" type="General" weightage="20" keywordseo="heart-disease" source="Orion">heart disease</keyword>, <keyword id="25191" type="General" weightage="20" keywordseo="stroke" source="Orion">stroke</keyword>, <keyword id="16753" type="General" weightage="20" keywordseo="blindness" source="Orion">blindness</keyword> or visual impairment, and kidney and nerve damage. LMICs are often faced with challenges such as inadequate infrastructure and trained healthcare staff with digital literacy. In that respect, the study's findings are crucial for integrating care models sustainably and identifying relevant organizational barriers. Previous studies from high-income countries showed improvements in diabetes care, but their long-term impact on vascular complications and mortality was unclear. This study aimed to address the critical gap in data regarding the long-term effectiveness of QI strategies and their impacts on vascular complications in LMICs. Professor Nikhil Tandon, Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, and senior author of the study explained the relevance of these findings in the context of national efforts to combat non-communicable diseases (NCDs). He said, "The <keyword id="22511956" type="General" weightage="20" keywordseo="National-Programme-for-NCDs" source="keywords">National Programme for NCDs</keyword> [NP-NCDs] operationalized by the Government of India has already a functional portal which provides an electronic health record functionality. Integrating the CDSS in this portal will provide significant incremental benefit to the impact of the National Programme, and bolster governmental efforts to battle the scourge of NCDs including diabetes and hypertension." Speaking about the findings, Prof. (Dr) Dorairaj Prabhakaran, Executive Director, CCDC, and one of the study authors, said, "Through the trial, we've demonstrated that a sustained quality improvement strategy can significantly enhance diabetes care and reduce complications in South Asia. For every 13 patients treated with this strategy, one major adverse cardiovascular event like heart attacks or strokes- or a microvascular event -like eye disease or decline in kidney function- was prevented, showcasing its profound impact on patient outcomes." Professor MK Ali, William H. Foege Distinguished Professor of Global Health, Emory University and one of the key authors of this article, said, "This study is an exemplar of trans-national collaboration for benefits of both, the global south and global north." Study Design and Findings The randomized clinical trial included 1,146 patients with poorly controlled type 2 diabetes across ten outpatient diabetes clinics from January 2011 through September 2019. Participants were randomized to receive either the QI strategy, which involved trained non-physician care coordinators and a clinical decision support software (CDSS) integrated into the electronic health record form, for physicians, or the usual care. Some of the key findings from the study include: <ul><li>At 6.5 years, patients in the QI strategy group were nearly twice as likely to achieve and maintain target levels for HbA1c (&lt;7%), systolic blood pressure (&lt;130mmHg), and LDL-cholesterol (&lt;100mg/dl), compared to the usual care group. </li><li> The incidence of first microvascular complications, such as diabetic eye disease, decline in kidney function, and nerve pain was notably 32% lower in the QI group. </li><li>There was a significant 28% reduction in the combined occurrence of microvascular and macrovascular events in the QI group.</li></ul> Importantly, these benefits were sustained only in clinics that continued the QI strategy for 6.5 years. With diabetes accounting for one in seven deaths in South Asia, the study provides unique insights into the sustainability of QI strategies in achieving diabetes care goals in low- and middle-income (LMICs) and the effects of these improvements on reducing vascular complications and diabetes-related deaths.

CCDC study reveals multi-pronged diabetes care improves patient outcomes in India, Pakistan

New Delhi, Dec 10 () Drug firm Panacea Biotec on Tuesday said it has launched its VilACT brand tablets available in four formulations, for treatment of type 2 diabetes in India.
 The four formulations are Vildagliptin 50 mg, Vildagliptin 50 mg + Metformin HCL 500 mg, Vildagliptin 50 mg + Metformin HCL 850 mg and Vildagliptin 50 mg + Metformin HCL 1,000 mg, Panacea Biotec said in a filing to the BSE.
 Vildagliptin product patent in India has expired on December 9, 2019 , it added.
 "Diacar Strategic Business Unit (SBU) has launched ViLACT brand family. This will open up a new segment for accelerated growth of the SBU," Panacea Biotec MD Rajesh Jain said.
Panacea Biotec has engineered its sales and marketing network for pharmaceutical formulations into SBUs, which comprise Oncotrust, Critical Care, Diacar, Procare and Growcare.
 As per the AIOCD MAT October 2019 data, the total market size of this molecule and its combination is Rs 969 crore and is growing at the rate of 4 per cent, Panacea Biotec said.
 The drug is used for "treatment of uncontrolled Type 2 Diabetes Mellitus patients," it added.
Panacea Biotec stock was trading at Rs 119 on the BSE, up 2.72 per cent from its previous close. AKT ANU

Panacea Biotec launches generic diabetes treatment drug in India

<keyword id="6354968" type="COMPANY" weightage="40" keywordseo="London">LONDON</keyword>: In a big breakthrough, Indian scientists have done what medical science has been trying to achieve since 1930 – an <keyword id="48003" type="UNKNOWN" weightage="60" keywordseo="insulin">insulin</keyword> pill for diabetics. 
 Since insulin’s crucial discovery nearly a century ago, countless <keyword id="6359018" type="UNKNOWN" weightage="40" keywordseo="diabetes">diabetes</keyword> patients have had to inject themselves with the life-saving medicine. 
 
Now Indian scientists have reported a new development toward a long-sought insulin pill that could save millions the pain of daily shots. 
 Published in the <keyword id="73594" type="ORGANIZATION" weightage="40" keywordseo="American-Chemical-Society">American Chemical Society</keyword> journal, the advance could someday not only eliminate the “ouch” factor but also get needle-wary — and weary — patients to take their medicine when they should. 
 
For years, researchers have sought a way to transform delivery of this therapy from a shot to a pill, but it has been a challenge. 
 
The body’s digestive enzymes that are so good at breaking down food also break down insulin before it can get to work. 
 
In addition, insulin doesn’t get easily absorbed through the gut into the bloodstream. 
 
To overcome these hurdles, Sanyog Jain from India’s National Institute of Pharmaceutical Education and Research combined two approaches to shield insulin from the digestive enzymes and then get it into the blood. 
 
They packaged insulin in tiny sacs made of lipids, or fats called liposomes, which are already used in some treatments. Then, they wrapped the liposomes in layers of protective molecules called polyelectrolytes. 
 
To help these “layersomes” get absorbed into the bloodstream, they attached folic acid, a kind of vitamin B that has been shown to help transport liposomes across the intestinal wall into the blood. 
 
In rats, the delivery system lowered blood glucose levels almost as much as injected insulin, though the effects of the “layersomes” lasted longer than that of injected insulin. 
 
Diabetes inhibits the production or use of insulin, which is a hormone that helps blood glucose or blood sugar become absorbed into cells and give them energy. 
 
Diabetes is one of India’s biggest health challenges. By 2030, India’s diabetes burden is expected to cross the 100 million mark, against 87 million estimated earlier. 
 
Type 1 diabetes occurs when the body doesn’t make enough insulin, and type 2 diabetes occurs when the body doesn’t make or use insulin very well, causing glucose to remain in the blood, which can lead to serious problems. 
 Libby Dowling, <keyword id="1983423" type="UNKNOWN" weightage="40" keywordseo="care-advisor">care advisor</keyword> at Diabetes UK, said “Oral insulin could make a big difference to the lives of people with diabetes. Children, elderly people and those with a phobia of needles would benefit particularly if and when insulin capsules become a safe and effective treatment for the condition. Although more research is needed, Diabetes UK would very much like to see insulin capsules one day become a reality.” 
 
She added, “Many people with Type 2 diabetes take diabetes tablets. They are not the same as insulin. As yet insulin cannot be taken in tablet form because it would be broken down in the stomach before it could work. Diabetes tablets work in different ways to lower blood glucose levels – for example by stimulating the pancreas to produce more insulin, or by helping the body to use the insulin that it does produce more effectively”

Indian Scientists Invent Insulin Pills For Diabetics

<ul><li><keyword id="2257489" type="PERSON" weightage="20" keywordseo="PM-Narendra-Modi">PM Narendra Modi</keyword> launches National Campaign for <keyword id="18974" type="COMPANY" weightage="20" keywordseo="fitness">fitness</keyword>. </li><li>India’s healthcare conditions aren’t getting better any sooner, without a large-scale movement on health. </li><li>India isn't on track to achieve any of the nine nutrition goals laid down by WHO by 2025. </li><li>Around 65 million people were diagnosed with diabetes in 2016 as opposed to 26 million in 1990. </li></ul>PM <keyword id="6354477" type="PERSON" weightage="20" keywordseo="Narendra-Modi">Narendra Modi</keyword> launches National Campaign for fitness. 
	
	
	<div type="twitter" handle="DDNewsLive" handlename="Doordarshan News" image="http://pbs.twimg.com/profile_images/1096030884937883649/9f1J7_Sa_normal.png" favoritecount="681" retweetcount="129" status="#NationalSportsDay: PM @narendramodi to launch #FitIndiaMovement across the country. Fit India movement aims to enc… https://t.co/ZYcZxeQU7P" createdat="1567039150000" id="1166872886281261056"></div>







 "We should make fitness our mantra for life,” Modi told while addressing a large crowd of children who put up a grand show ahead of the launch at the Indira Gandhi Stadium Complex. Modi is also a staunch advocate of Yoga."Yoga is a discipline. Yoga is beyond age, caste, religion, region, and boundaries. Yoga sabka hai aur sab yoga ke hain,” he said on June 21 while celebrating <keyword id="6362857" type="DEFINITION" weightage="20" keywordseo="international-yoga-day">international Yoga day</keyword>. The Indian government is also trying to turn Yoga asanas or postures into a sport. All these initiatives come at a time when a large number of Indians are suffering from lifestyle diseases. India to miss all of WHO's 9 nutrition goals According to the 2018 Global Nutrition Report, India isn't on track to achieve any of the nine nutrition goals laid down by WHO including -- reducing adult and childhood obesity, wasting and stunting, diabetes, anaemia in women of reproductive age, and increase exclusive breastfeeding by 2025. India also holds the dubious distinction of being the diabetes capital of the world. Around 65 million people were diagnosed with diabetes in 2016 as opposed to 26 million in 1990. As many as 35% of diabetics also suffer from obesity. The number of overweight adults otherwise also surged to 21% in 2016. The three greatest threats to human health around the world include undernutrition, obesity, and climate change<a href="https://www.businessinsider.in/poor-diet-obesity-and-climate-change-strongly-linked-lancet-report/articleshow/67722970.cms"> warned a recent study by Lancet.</a> Indians love to eat well and just won't go on a diet Few Indians abstain from food to take up healthy habits as well. As per <a href="https://www.ipsos.com/sites/default/files/ct/news/documents/2018-12/todays-views-that-will-shape-tomorrows-food-ppt-2018-12-05-v1.pdf">a survey</a>, Indias prefer to 'eat well' over sacrificing food for health. The survey says as few as 33% people believe that being thin is more important than eating well. Interestingly, 74% of the respondents said they were content with their current weight. However, 57% have tried a diet to lose weight, diet plans of 59% who tried it, failed.

You Searched For "Diabetes in india" and got 9 results

Horlicks taps into the segment of diabetes; launches a new campaign to highlight the importance of fibre consumption for diabetic patients

BI India Partner

What diabetics should know about the deadly 'black fungus' infections affecting India's COVID-19 patients

Kelsie Sandoval

Zydus Cadila gets DGCI nod for diabetes treatment drug

PTI

Zydus Cadila launches affordable oral anti-diabetic tablets in India as drug goes off patent

PTI

These are the top-selling anti-diabetes drugs in India

BI India Bureau

CCDC study reveals multi-pronged diabetes care improves patient outcomes in India, Pakistan

ANI

Panacea Biotec launches generic diabetes treatment drug in India

PTI

Indian Scientists Invent Insulin Pills For Diabetics

Times Of India

Modi launches fit India movement as the country battles its diabetes capital tag

BI India Bureau

Popular Keywords

Buying Guides